SCHEDULE 13G/A: Nantahala Capital Management Discloses 4.38% Passive Stake in Zevra Therapeutics

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.38% in Zevra Therapeutics, Inc. as of December 31, 2024.

Summary

• Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership of ZEVRA THERAPEUTICS, INC. common stock.
• As of December 31, 2024, the Reporting Persons collectively beneficially own 2,340,333 shares of Zevra Therapeutics, Inc. Common Stock.
• This ownership represents 4.38% of the total outstanding shares of Zevra Therapeutics, Inc.
• The filing indicates that the shares are held with shared voting power and shared dispositive power for all 2,340,333 shares, with no sole voting or dispositive power.
• Nantahala Capital Management, LLC is classified as an Investment Adviser (IA), while Wilmot B. Harkey and Daniel Mack are classified as Control Persons (HC).
• The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual, regulatory filing disclosing beneficial ownership. It does not contain information that would typically indicate positive or negative sentiment regarding the company's performance or outlook, beyond the implicit signal of a significant investor holding a stake.

Positives

• The filing indicates a significant passive investment by Nantahala Capital Management, a notable investment adviser, which could be interpreted as a vote of confidence in Zevra Therapeutics by a sophisticated investor.

Negatives

• The document does not contain information that would typically be categorized as negative, as it is a routine beneficial ownership disclosure.

Risks

• The document itself does not detail specific risks related to Zevra Therapeutics' operations or financial performance, as it is a beneficial ownership report.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Zevra Therapeutics' future performance or strategic direction.

Industry Context

This filing is a standard regulatory disclosure (Schedule 13G) required when an investor or group acquires beneficial ownership of more than 5% of a company's voting class of securities, or in this case, an amendment to a previous filing. It provides transparency on significant passive ownership stakes, which can signal investor confidence or strategic positioning within the biotechnology or pharmaceutical industry, where Zevra Therapeutics operates.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant passive investor's stake, which may influence market perception and trading activity.
• Investment Professionals: Offers insight into the holdings of Nantahala Capital Management, a recognized investment adviser, for their portfolio analysis.

Key Dates

Keywords

Zevra Therapeutics, Nantahala Capital Management, Beneficial Ownership, Schedule 13G, SEC Filing, Common Stock, Investment Adviser, Passive Investment